Entry Point Capital, LLC Ionis Pharmaceuticals Inc Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding IONS
# of Institutions
402Shares Held
136MCall Options Held
862KPut Options Held
582K-
Vanguard Group Inc Valley Forge, PA15.1MShares$547 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD14.2MShares$515 Million0.34% of portfolio
-
Black Rock Inc. New York, NY10.3MShares$375 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.74MShares$317 Million0.06% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.87MShares$286 Million5.32% of portfolio
About IONIS PHARMACEUTICALS INC
- Ticker IONS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 141,940,992
- Market Cap $5.16B
- Description
- Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...